HTH-02-006

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 465029

CAS#: Unknown

Description: HTH-02-006 ameliorates YAP(S127A)-induced hepatomegaly, and reduces MYPT1(S445) phosphorylation in the same tissues. HTH-02-006 delays the outgrowth of YAP-induced HuCCT-1 xenograft tumors in nude mice, supposedly through NUAK2 inhibition. HTH-02-006 is a reversible small-molecule inhibitor of the Hippo pathway kinase, NUAK2. It can be used as a tool compound to investigate the role of NUAK2 in cancer and other Hippo pathway-associated biological processes. HTH-02-006 is a derivative of the prototype NUAK inhibitor WZ4003. It is active in vivo.

Chemical Structure

img
HTH-02-006
CAS# Unknown
Instruction

Theoretical Analysis

MedKoo Cat#: 465029
Name: HTH-02-006
CAS#: Unknown
Chemical Formula: C25H29IN6O3
Exact Mass: 588.13
Molecular Weight: 588.450
Elemental Analysis: C, 51.03; H, 4.97; I, 21.57; N, 14.28; O, 8.16

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: HTH-02-006; HTH02006; HTH 02 006; HTH-02006; HTH 02006; HTH02006;

IUPAC/Chemical Name: N-(3-((5-iodo-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin4-yl)oxy)phenyl)propionamide

InChi Key: KQMWYEJQANQTDM-UHFFFAOYSA-N

InChi Code: InChI=1S/C25H29IN6O3/c1-4-23(33)28-17-6-5-7-19(14-17)35-24-20(26)16-27-25(30-24)29-21-9-8-18(15-22(21)34-3)32-12-10-31(2)11-13-32/h5-9,14-16H,4,10-13H2,1-3H3,(H,28,33)(H,27,29,30)

SMILES Code: IC1=CN=C(NC2=C(OC)C=C(N3CCN(C)CC3)C=C2)N=C1OC4=CC=CC(NC(CC)=O)=C4

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 588.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1. Dey A, Varelas X, Guan KL. (2020) Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine. Nat Rev Drug Discov, 19 (7): 480-494. [PMID:32555376]

2. Juan WC, Hong W. (2016) Targeting the Hippo Signaling Pathway for Tissue Regeneration and Cancer Therapy. Genes (Basel), 7 (9). [PMID:27589805]

3. Yuan WC, Pepe-Mooney B, Galli GG, Dill MT, Huang HT, Hao M, Wang Y, Liang H, Calogero RA, Camargo FD. (2018) NUAK2 is a critical YAP target in liver cancer. Nat Commun, 9 (1): 4834. [PMID:30446657]